<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259571</url>
  </required_header>
  <id_info>
    <org_study_id>PC4</org_study_id>
    <secondary_id>EC - L389/2003</secondary_id>
    <secondary_id>BFARM - 402 2918</secondary_id>
    <nct_id>NCT00259571</nct_id>
  </id_info>
  <brief_title>Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.</brief_title>
  <official_title>Prospektive, Randomisierte, Doppelblinde, Mesalazin-kontrollierte (&quot;Double-dummy Verfahren) Multizenter-Studie Zur Beurteilung Der Annahme Der äquivalenten Wirkung Von Intestinal Retardiert Freigesetztem Phosphatidylcholin gegenüber Mesalazin (Non-inferiority Study) in Der Remissionserhaltung Der Colitis Ulcerosa.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dietmar Hopp Stiftung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if retarded phosphatidylcholine is as effective as
      mesalazin in preventing an acute episode in ulcerative colitis.

      The hypothesis is, that ulcerative colitis is cuased by a defect in the barrier function of
      the colonic mucus. The background of the study is the finding that the phosphatidylcholine
      content of the colonic mucus is reduced in patients with ulcerative colitis, in both healthy
      and inflamed parts of the colon.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Missing financial sponsorship
  </why_stopped>
  <completion_date>March 2010</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of relapses</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>relapse is defined as an increase of the clinical Rachmilewitz index to 5 or more, but at least 3 points over a period of 14 days</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to the first relapse</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of relapses per year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endoscopic index</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>histolgical score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>life quality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Ulcerative Colitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>retarded release phosphatidylcholine</intervention_name>
    <description>2g daily, given orally QTD</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of ulcerative colitis in remission (CAI 3 or less)

          -  signed letter of content

          -  no steroids or immunosupressants in the last 6 weeks

          -  at least 5 relapses in the last 3 years

          -  last relapse was 8 months ago or less

          -  complete colonoscopy at entry

        Exclusion Criteria:

          -  pregnancy or breast feeding

          -  steroids or immunosuppressants

          -  acute episode of UC

          -  condition after complete or partial colektomy

          -  known intolerance to mesalazin

          -  severe medical disease other than colitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Stremmel, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Hospital - University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut. 2005 Jul;54(7):966-71.</citation>
    <PMID>15951544</PMID>
  </reference>
  <verification_date>November 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2005</study_first_submitted>
  <study_first_submitted_qc>November 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>December 12, 2013</last_update_submitted>
  <last_update_submitted_qc>December 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <keyword>remission</keyword>
  <keyword>mesalazin</keyword>
  <keyword>non-inferiority study</keyword>
  <keyword>relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

